The International Formulary ... PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download The International Formulary ... PDF full book. Access full book title The International Formulary ... by A. Emil Hiss. Download full books in PDF and EPUB format.
Author: A. Emil Hiss
Publisher:
ISBN:
Category : Formulas, recipes, etc
Languages : en
Pages : 580
Get Book Here
Book Description
Author: A. Emil Hiss
Publisher:
ISBN:
Category : Formulas, recipes, etc
Languages : en
Pages : 580
Get Book Here
Book Description
Author: British Medical Association
Publisher:
ISBN: 9780857113313
Category : Drugs
Languages : en
Pages : 0
Get Book Here
Book Description
Compiled with the advice of clinical experts and continually updated to reflect the latest evidence from credible sources worldwide, the new edition of the British National Formulary 75 (BNF) provides up-to-date guidance on prescribing, dispensing, and administering medicines. Access to the latest edition of the BNF is vital for healthcare professionals, as it reflects current best practice as well as legal and professional guidelines relating to the uses of medicines. NICE has accredited the editorial process used by the British National Formulary to produce its resources.
Author: Richard Krever
Publisher: Kluwer Law International B.V.
ISBN: 9403506156
Category : Law
Languages : en
Pages : 314
Get Book Here
Book Description
The Allocation of Multinational Business Income: Reassessing the Formulary Apportionment Option Edited by Richard Krever & François Vaillancourt Although arm’s length methodology continues to prevail in international taxation policy, it has long been replaced by the formulary apportionment method at the subnational level in a few federal countries. Its use is planned for international profit allocation as an element of the European Union’s CCCTB proposals. In this timely book – a global guide to formulary apportionment, both as it exists in practice and how it might function internationally – a knowledgeable group of contributors from Australia, Canada, the United Kingdom and the United States, address this actively debated topic, both in respect of its technical aspects and its promise as a global response to the avoidance, distortions, and unfairness of current allocation systems. Drawing on a wealth of literature considering formulary apportionment in the international sphere and considering decades of experience with the system in the states and provinces of the United States and Canada, the contributors explicate and examine such pertinent issues as the following: the debate about what factors should be used to allocate profits under a formulary apportionment system and experience in jurisdictions using formulary apportionment; application of formulary apportionment in specific sectors such as digital enterprises and the banking industry; the political economy of establishing and maintaining a successful formulary apportionment regime; formulary apportionment proposals for Europe; the role of traditional tax criteria such as economic efficiency, fairness, ease of administration, and robustness to avoidance and incentive compatibility; determining which parts of a multinational group are included in a formulary apportionment unit; and whether innovative profit-split methodologies such as those developed by China are shifting traditional arm’s length methods to a quasi-formulary apportionment system. Providing a comprehensive understanding of all aspects of the formulary apportionment option, this state of the art summary of history, current practice, proposals and prospects in the ongoing debate over arm’s length versus formulary apportionment methodologies will be welcomed by practitioners, policy-makers, and academics concerned with international taxation, all of whom will gain an understanding of the case put forward by proponents for adoption of formulary apportionment in Europe and globally and the counter-arguments they face. Readers will acquire a better understanding of the implications of formulary apportionment and its central role in the current debate about the future of international taxation rules. “...providing (sic) all the intellectual ammunition needed to carefully re-examine one of the ideas traditionally considered as apocryphal by the OECD and to a significant portion of the tax professional community...readers of this book will come away not only with a renewed understanding of the multiple facets of formulary apportionment, but also of some of the fundamental pressure points in the international tax system. Accordingly, it is a welcome and timely addition to the literature. ” Dr. Stjepan Gadžo, Assistant Professor at University of Rijeka, Faculty of Law / British Tax Review 2021, Issue 2, p243-246
Author: Sean Ainsworth
Publisher: Oxford University Press
ISBN: 0192577263
Category : Medical
Languages : en
Pages : 992
Get Book Here
Book Description
Neonatal Formulary provides comprehensive guidance on the safe use of the drugs prescribed during pregnancy and commonly given to babies during labour and delivery, as well as during lactation and the first year of life. Treating the journey from pregnancy to parenthood as a continuous event, the new edition contains updated information on how the drugs affect both mother and baby. The first part of the book focuses on drug storage, drug licensing, and drug prescribing. In addition, it explains to why the metabolism of drugs differs in premature and sick infants, and why the practice of extrapolating doses from adult studies is unsafe. Patient safety, excipients, and therapies that affect drugs are also covered. Part 2 consists of monographs for over 250 drugs that may find use in the neonatal unit, and possibly outside it. Each monograph is divided into sections covering use, pharmacology, treatment, drug interactions or other administration, information, supply and administration, and references. The monographs are evidence-based and include links to the Cochrane Database of Systematic Reviews, and national guidelines. The third part presents information on additional drugs, and groups of drugs, that are often taken by mothers during pregnancy, labour, or during breast feeding. The drugs discussed in this section all affect the foetus or infant. Containing far more detail than is available in the British National Formulary for Children, and with additional online material featuring updates related to specific drugs and dosing, Neonatal Formulary is an essential guide for neonatologists, neonatal nurses, hospital pharmacists, obstetric staff, advanced nurse practitioners and for all health care professionals caring for pregnant women and their infants in the first year of life.
Author: WHO Expert Committee on the Selection and Use of Essential Medicines
Publisher: WHO
ISBN:
Category : Medical
Languages : en
Pages : 144
Get Book Here
Book Description
This report presents the recommendations of the WHO Expert Committee responsible for updating the WHO Model List of Essential Medicines. The first part contains a progress report on the new procedures for updating the Model List and the development of the WHO Essential Medicines Library. It continues with a section on changes made in revising the Model List followed by a review of some sections such as hypertensive medicines and fast track procedures for deleting items. Annexes include the 13th version of the Model List and items on the list sorted according to their 5-level Anatomical Therapeutic Chemical classification codes.
Author: British Medical Association
Publisher:
ISBN: 9780857114112
Category :
Languages : en
Pages :
Get Book Here
Book Description
Author: C. Terrance Hawk
Publisher: Wiley-Blackwell
ISBN: 9780813810485
Category : Medical
Languages : en
Pages : 203
Get Book Here
Book Description
Formulary for Laboratory Animals is an invaluable reference for treatment of laboratory animals and pocket pets. Drugs are listed alphabetically and categorized in five sections based on pharmacologic activity and animal species. This at-a-glance pocket reference is valuable for students and practitioners of veterinary medicine, researchers and laboratory technicians who prescribe or administer drugs used on common laboratory animals. The third edition includes a stronger international component, coverage of several new drugs, hundreds of additional dosages, and a thorough update throughout based on the most current research. The third edition also includes a chapter describing how to estimate drug dosages among species using allometric scaling methodology.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309468086
Category : Medical
Languages : en
Pages : 235
Get Book Here
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author:
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 1042
Get Book Here
Book Description
Author: Sheila Shulman
Publisher: CRC Press
ISBN: 9780789005120
Category : Medical
Languages : en
Pages : 216
Get Book Here
Book Description
PBMs: Reshaping the Pharmaceutical Distribution Network provides HMOs and other third-party payers with information on the new and increasingly important role of pharmaceutical benefit companies (PBMs) in the health care industry. From this text, you will learn how PBMs can maintain and deliver a quality, cost-effective drug benefit plan to your company while achieving the anticipated market share for the product. PBMs: Reshaping the Pharmaceutical Distribution Network offers you suggestions on how to choose which PBM service is correct for your business, such as what qualifications to look for in a PBM, as well as what questions you should ask a respective company. This text also offers ways on how your company can benefit from becoming a client and may make your business more competitive in the pharmaceutical industry. PBMs: Reshaping the Pharmaceutical Distribution Network also informs you about the controversies that have arisen concerning the new position of PBMs in the industry. Through research and evaluation, this text addresses these issues from many different perspectives and gives you insight into other topics concerning PBMs, including: operating methods that PBMs currently rely on for designing and overseeing a drug benefit plan how the Food and Drug Administration currently views the role of PBMs and why they are contemplating regulatory intervention alerting PBMs, pharmacies, pharmaceutical companies, and managed care organizations to new legal issues involving fraud and abuse affecting pharmacy benefit management and pharmaceutical manufacturers reasons why retail drug chains and pharmacist organizations oppose recent industry developments regarding PBMs whether or not PBMs reflect a move toward greater centralized decisionmaking in the health care systemIn addition, PBMs: Reshaping the Pharmaceutical Distribution Network offers pharmaceutical companies, health care providers, and managed care organizations several suggestions for further research, which may make your business or your business relationships more efficient and productive in the future. If you or your company are considering the services of a pharmacy benefit management, PBMs: Reshaping the Pharmaceutical Distribution Network will guide you in choosing a company that helps you deliver the most cost-effective and efficient pharmaceutical benefits to customers.
